What changed
What changedIn the week ended November 16, 2026, AstraZeneca received several regulatory approvals, including EU authorization for Klygefa to treat myasthenia gravis. The company also announced US approval of Imfinzi for bladder cancer and a CHMP recommendation for Baxfendy to treat hypertension.

What changedBetween October 22 and October 27, 2026, AstraZeneca received two major regulatory approvals: US accelerated approval for Ultomiris and European Union approval for Enhertu. These events expand the company’s commercial portfolio in rare diseases and oncology.

Company history
October 2026
ASTRAZENECA PLC: 12 recorded developments from 2 official sources in 2026-10.
- 2026-10-22: AstraZeneca Rare Disease's Alexion received US accelerated approval for Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. Source
- 2026-10-22: AstraZeneca is a global, science-led biopharmaceutical company focused on oncology, rare disease, and biopharmaceuticals, including cardiovascular, renal, metabolism, respiratory, and immunology. Source
- 2026-10-22: In the I CAN Phase III trial, Ultomiris demonstrated a 43.4% placebo-adjusted reduction in proteinuria at 34 weeks. Source
- 2026-10-22: In the I CAN Phase III trial, patients treated with Ultomiris demonstrated a 46.6% reduction in 24-hour urine protein creatinine ratio from baseline at week 34. Source
- 2026-10-22: The safety profile of Ultomiris observed in the I CAN trial was consistent with its known profile and generally well tolerated, with no new safety concerns identified. Source
- 2026-10-22: Regulatory submissions based on the interim results from the I CAN trial are under review in Japan and additional countries. Source
- 2026-10-27: Enhertu has been approved in the European Union as a monotherapy for the adjuvant treatment of adult patients with resected HER2-positive breast cancer with residual invasive disease. Source
- 2026-10-27: In the DESTINY-Breast05 trial, Enhertu reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1. Source
- 2026-10-27: A $75 million milestone payment is due from AstraZeneca to Daiichi Sankyo following the EU approval for the adjuvant HER2-positive early breast cancer indication. Source
- 2026-10-27: Enhertu (5.4mg/kg) is approved in more than 35 countries worldwide for the adjuvant treatment of adult patients with HER2-positive breast cancer who have residual invasive disease following neoadjuvant therapy. Source
- 2026-10-27: Enhertu (6.4mg/kg) is approved in more than 90 countries worldwide for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Source
- 2026-10-27: AstraZeneca has a breast cancer portfolio with five approved medicines across 12 indications and seven ongoing Phase III trials. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The company aims to bring 20 new medicines to the world by 2030.
Said November 16, 2026 · Period named: 2030 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| Norges Bank (Norway's sovereign fund) | 33,864,172 | $6,334,634,620 | — | Q2 2026 |
| Wellington Management | 30,837,503 | $5,010,413,003 | +8.1% | Q3 2026 |
| Fidelity (FMR) | 29,383,096 | $4,775,097,854 | +1.7% | Q3 2026 |
| Capital Research Global Investors | 5,332,987 | $867,473,075 | +27.0% | Q3 2026 |
| D. E. Shaw & Co. | 4,775,972 | $771,176,199 | +336.3% | Q3 2026 |
| BlackRock | 2,046,756 | $330,489,627 | -5.7% | Q3 2026 |
| Citadel Advisors | 1,799,064 | $290,494,864 | +85.5% | Q3 2026 |
| State Street | 994,107 | $160,518,457 | +283.7% | Q3 2026 |
| Millennium Management | 993,727 | $160,457,099 | +70.8% | Q3 2026 |
| Renaissance Technologies | 98,272 | $15,867,980 | — | Q3 2026 |
| Two Sigma Investments | 95,066 | $15,350,307 | -71.1% | Q3 2026 |
| T. Rowe Price | 19,287,243 | $3,114,312 | +16.1% | Q3 2026 |
| Bridgewater Associates | 8,188 | $1,322,116 | — | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.